06.27.06
Wyeth submitted two NDAs to the FDA, one for bazedoxifene, a Selective Estrogen Receptor Modulator (SERM) investigated for the prevention of postmenopausal osteoporosis, and one for desvenlafaxine succinate, a non-hormonal agent studied for the treatment of moderate to severe vasomotor symptoms associated with menopause.
According to the National Osteoporosis Foundation the number of women of menopausal age who have osteoporosis or are at risk for developing the disease will increase from almost 30 million in 2002 to nearly 41 million in 2020. Also, there are approximately 40 million women in the U.S. of menopausal age. As many as 93% of women going through menopause experience vasomotor symptoms such as hot flashes but many women remain untreated for their vasomotor symptoms, according to the North American Menopause Society.
According to the National Osteoporosis Foundation the number of women of menopausal age who have osteoporosis or are at risk for developing the disease will increase from almost 30 million in 2002 to nearly 41 million in 2020. Also, there are approximately 40 million women in the U.S. of menopausal age. As many as 93% of women going through menopause experience vasomotor symptoms such as hot flashes but many women remain untreated for their vasomotor symptoms, according to the North American Menopause Society.